FRANK A GRECO
Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology NASHVILLE, TN NPI 1497791602
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology TN Acerta Pharma LLC All categories
General Payments — all program years on this page
$5,123.34
- Category: General Payments
- Program years: PY2018–2024
- Record count: 263
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,131.27 across 50 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,131.27 | 50 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Acerta Pharma LLC | $147.89 | 7 |
| Merck Sharp & Dohme Corporation | $102.16 | 4 |
| ABIOMED | $61.00 | 2 |
| Bayer HealthCare Pharmaceuticals Inc. | $58.45 | 3 |
| Alexion Pharmaceuticals, Inc. | $55.83 | 2 |
| ABBVIE INC. | $50.63 | 2 |
| Janssen Biotech, Inc. | $48.58 | 2 |
| Deciphera Pharmaceuticals Inc. | $43.40 | 2 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $43.15 | 2 |
| Mirati Therapeutics, Inc. | $42.28 | 2 |
| Celgene Corporation | $40.30 | 2 |
| Gilead Sciences, Inc. | $39.95 | 2 |
| PUMA BIOTECHNOLOGY, INC. | $39.35 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $39.11 | 2 |
| E.R. Squibb & Sons, L.L.C. | $36.38 | 2 |
| PFIZER INC. | $34.60 | 2 |
| GENZYME CORPORATION | $31.59 | 1 |
| Rigel Pharmaceuticals, Inc. | $29.80 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $29.65 | 1 |
| TerSera Therapeutics LLC | $28.04 | 1 |
| Regeneron Healthcare Solutions, Inc. | $27.49 | 1 |
| GlaxoSmithKline, LLC. | $27.15 | 1 |
| Genmab U.S., Inc. | $24.86 | 1 |
| SERVIER PHARMACEUTICALS LLC | $18.21 | 1 |
| Sumitomo Pharma America, Inc. | $17.24 | 1 |
| TAIHO ONCOLOGY, INC. | $14.18 | 1 |
By program year
Records — PY2024 (50)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.